These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 21403972)

  • 1. The mass-action law based algorithms for quantitative econo-green bio-research.
    Chou TC
    Integr Biol (Camb); 2011 May; 3(5):548-59. PubMed ID: 21403972
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies.
    Chou TC
    Pharmacol Rev; 2006 Sep; 58(3):621-81. PubMed ID: 16968952
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug combination studies and their synergy quantification using the Chou-Talalay method.
    Chou TC
    Cancer Res; 2010 Jan; 70(2):440-6. PubMed ID: 20068163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The mass-action law based algorithm for cost-effective approach for cancer drug discovery and development.
    Chou TC
    Am J Cancer Res; 2011; 1(7):925-54. PubMed ID: 22016837
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biosimulation software is changing research.
    Ho RL; Bartsell LT
    Biotechnol Annu Rev; 2004; 10():297-302. PubMed ID: 15504712
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fitting models for the joint action of two drugs using SAS.
    Whitehead A; Whitehead J; Todd S; Zhou Y; Smith MK
    Pharm Stat; 2008; 7(4):272-84. PubMed ID: 17979217
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determining the error of dose estimates and minimum and maximum acceptable concentrations from assays with nonlinear dose-response curves.
    Gottschalk PG; Dunn JR
    Comput Methods Programs Biomed; 2005 Dec; 80(3):204-15. PubMed ID: 16256244
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The analysis of dose-response curve from bioassays with quantal response: Deterministic or statistical approaches?
    Mougabure-Cueto G; Sfara V
    Toxicol Lett; 2016 Apr; 248():46-51. PubMed ID: 26952004
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SysBioMed report: advancing systems biology for medical applications.
    Wolkenhauer O; Fell D; De Meyts P; Blüthgen N; Herzel H; Le Novère N; Höfer T; Schürrle K; van Leeuwen I
    IET Syst Biol; 2009 May; 3(3):131-6. PubMed ID: 19449974
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mathematical modeling of drug delivery.
    Siepmann J; Siepmann F
    Int J Pharm; 2008 Dec; 364(2):328-43. PubMed ID: 18822362
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical versus clinical drug combination studies.
    Chou TC
    Leuk Lymphoma; 2008 Nov; 49(11):2059-80. PubMed ID: 19021049
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In silico prediction of harmful effects triggered by drugs and chemicals.
    Vedani A; Dobler M; Lill MA
    Toxicol Appl Pharmacol; 2005 Sep; 207(2 Suppl):398-407. PubMed ID: 16045954
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A mechanistic, predictive model of dose-response curves for cell cycle phase-specific and -nonspecific drugs.
    Gardner SN
    Cancer Res; 2000 Mar; 60(5):1417-25. PubMed ID: 10728708
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Computational systems biology and dose-response modeling in relation to new directions in toxicity testing.
    Zhang Q; Bhattacharya S; Andersen ME; Conolly RB
    J Toxicol Environ Health B Crit Rev; 2010 Feb; 13(2-4):253-76. PubMed ID: 20574901
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Addressing nonlinearity in the exposure-response relationship for a genotoxic carcinogen: cancer potency estimates for ethylene oxide.
    Kirman CR; Sweeney LM; Teta MJ; Sielken RL; Valdez-Flores C; Albertini RJ; Gargas ML
    Risk Anal; 2004 Oct; 24(5):1165-83. PubMed ID: 15563286
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Future of toxicology--low-dose toxicology and risk--benefit analysis.
    Rietjens IM; Alink GM
    Chem Res Toxicol; 2006 Aug; 19(8):977-81. PubMed ID: 16918235
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New approaches to drug discovery and development: a mechanism-based approach to pharmaceutical research and its application to BNP7787, a novel chemoprotective agent.
    Hausheer FH; Kochat H; Parker AR; Ding D; Yao S; Hamilton SE; Petluru PN; Leverett BD; Bain SH; Saxe JD
    Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S3-15. PubMed ID: 12819940
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Linear interpolation algorithm for low dose risk assessment of toxic substances.
    Gaylor DW; Kodell RL
    J Environ Pathol Toxicol; 1980 Nov; 4(5-6):305-12. PubMed ID: 7217854
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A modular approach for integrative analysis of large-scale gene-expression and drug-response data.
    Kutalik Z; Beckmann JS; Bergmann S
    Nat Biotechnol; 2008 May; 26(5):531-9. PubMed ID: 18464786
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of drug efficacy regions based on dosage and frequency schedules.
    Li XL; Qian L; Bittner ML; Dougherty ER
    IEEE Trans Biomed Eng; 2011 Mar; 58(3):488-98. PubMed ID: 21095860
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.